Liu Li, Guo Wuhua, Zhang Jixiang
The Second Affiliated Hospital of Nanchang University, Nanchang, China.
The Second Affiliated Hospital of Nanchang University, Nanchang, China -
Minerva Med. 2017 Apr;108(2):176-184. doi: 10.23736/S0026-4806.16.04571-7. Epub 2016 Nov 3.
The study aimed to assess the association between human leukocyte antigen (HLA)-DRB1 allele polymorphisms and hepatocellular carcinoma (HCC) susceptibility.
Relevant case-control studies on HLA-DRB1 allele correlation with HCC risk published between 2000 and 2015 were searched and retrieved in literature database. The odds ratio (OR) with its 95% confidence interval (CI) were employed to calculate the strength of association. Total 16 articles including 2208 HCC patients and 3028 relevant controls were finally screened out.
A total of 12 case-control studies including 2030 HCC patients and 2817 relevant controls were screened out. Thirteen alleles (HLA-DRB1 *01, *03, *04, *07, *08, *09, *10, *11, *12, *13, *14, *15, and *16) were reported. Overall, we found that HLA-DRB1 *1 and *11 allele polymorphisms were significantly associated with decreased the HCC risk (*1: OR=0.53, 95% CI: 0.29-0.96, P=0.04; *11: OR=0.58, 95% CI: 0.38-0.88, P=0.010); while *12 and *14 allele polymorphisms were significantly associated with increased the HCC risk (*12: OR=1.49, 95% CI: 1.08-2.07, P=0.02; *14: OR=1.89, 95% CI: 1.27-2.82, P=0.002) in a fixed-effect model. However, other HLA-DRB1 allele polymorphisms were not associated with HCC susceptibility (P>0.05).
HLA-DRB1 *1 and *11 allele polymorphisms were protective factors, *12 and *14 allele polymorphisms were risk factors for HCC development. Future large-scale studies with more ethnicities are still needed.
本研究旨在评估人类白细胞抗原（HLA）-DRB1等位基因多态性与肝细胞癌（HCC）易感性之间的关联。
检索了2000年至2015年间发表的关于HLA-DRB1等位基因与HCC风险相关性的相关病例对照研究，并从文献数据库中获取相关信息。采用比值比（OR）及其95%置信区间（CI）来计算关联强度。最终筛选出16篇文章，包括2208例HCC患者和3028例相关对照。
共筛选出12项病例对照研究，包括2030例HCC患者和2817例相关对照。报告了13个等位基因（HLA-DRB1 *01、*03、*04、*07、*08、*09、*10、*11、*12、*13、*14、15和16）。总体而言，我们发现HLA-DRB1 1和11等位基因多态性与降低HCC风险显著相关（*1：OR=0.53，95%CI：0.29-0.96，P=0.04；*11：OR=0.58，95%CI：0.38-0.88，P=0.010）；而在固定效应模型中，12和14等位基因多态性与增加HCC风险显著相关（*12：OR=1.49，95%CI：1.08-2.07，P=0.02；*14：OR=1.89，95%CI：1.27-2.82，P=0.002）。然而，其他HLA-DRB1等位基因多态性与HCC易感性无关（P>0.05）。
HLA-DRB1 1和11等位基因多态性是保护因素，12和14等位基因多态性是HCC发生的危险因素。未来仍需要开展更多涉及更多种族的大规模研究。
